Across TCGA pan-cancer cohorts, ANKRD39 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANKRD39 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ANKRD39 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD39 expression acts as an unfavorable survival marker.

BRCA and ACC are the cancer types where ANKRD39 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.166	0.579	.022	8	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ANKRD39 tumor-vs-normal RNA expression · all ANKRD39 data types